Basilea Pharmaceutica Ltd. Logo

Anti-Infectives 2012



  • Bush K. Improving known classes of antibiotics: An optimistic approach for the future. Curr Opin Pharmacol. 2012; 12(5): 527-534.
  • Chong YP, Park S-J, Kim HS, Kim ES, Kim M-N, Kim S-H, Lee S-O, Choi S-H, Jeong J-Y, Woo JH, Kim YS. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: Stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis. 2012; 73(3): 264-266.
  • Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob. Agents. 2012; 39(6): 534-538.
  • Eichenbaum G, Skibbe J, Parkinson A, Johnson MD, Baumgardner D, Ogilvie B, Usuki E, Tonelli F, Holsapple J, Schmitt-Hoffmann A. Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: A case study example with the prodrug ceftobiprole medocaril. J Pharm Sci. 2012; 101(3): 1242-1252.
  • Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK, Lynch AS. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2012; 56(3): 1476-1484.
  • Lovering AL, Gretes MC, Safadi SS, Danel F, De Castro L, Page MGP, Strynadka NCJ. Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J Biol Chem. 2012; 287(38): 32096-32102. 
  • Nicholson SC, Welte T, File Jr TM, Strauss RS, Michiels B, Kaul P, Balis D, Arbit D, Amsler K, Noel GJ. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012; 39(3): 240-246.
  • Saleh-Mghir A, Dumitrescu O, Dinh A, Boutrad Y, Massias L, Martin É, Vandenesch F, Etienne J, Lina G, Cremieux AC. Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 2012; 56(12): 6291-6297. 
  • Singh KV, Murray BE. Efficacy of ceftobiprole medocaril against Enterococcus faecalis in a murine urinary tract infection model. Antimicrob Agents Chemother. 2012; 56(6): 3457-3460. 
  • Stucki A, Cottagnoud M, Acosta F, Egerman U, Läuffer J, Cottagnoud P. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother. 2012; 56(2): 921-925.
  • Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: Focus on the study design. Mayo Clin Proc. 2012; 87(4): 349-363.
52nd Interscience Congress on Antimicrobial Agents and Chemotherapy ICAAC, September 2012, San Francisco, United States of America
  • A-624 / %fT>MIC Predicts Probability of Microbiological Outcome in the Treatment of Nosocomial Pneumonia by Ceftobiprole. Muller AE, Punt N, Mouton JW.
  • A-624a / Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: A Validation Study. Muller A, Schmitt-Hoffmann AH, Punt N, Mouton JW.


  • Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012; 67(2): 362-366.
  • Feng P, Najafzadeh MJ, Sun J, Abdalla Ahmed S, Xi L, Curfs-Breuker I, Meis JF, De Hoog GS. In vitro activities of nine antifungal drugs against 81 isolates of cutaneous fungi in Phialophora and Cyphellophora. Mycoses. 2012; 55: 124.
  • Feng P, Najafzadeh MJ, Sun J, Ahmed S, Xi L, De Hoog GS, Lai W, Lu C, Klaassen CH, Meis JF. In Vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates. Antimicrob Agents Chemother. 2012; 56(11): 6044-6047.
  • Hagen F, Illnait-Zaragozí M-T, Meis JF, Chew WHM, Curfs-Breuker I, Mouton JW, Hoepelman AIM, Spanjaard L, Verweij PE, Kampinga GA, Kuijper EJ, Boekhout T, Klaassen CHW. Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. J Clin Microbiol. 2012; 50(6): 1918-1926.
  • Kathuria S, Klaassen CH, Roy P, Najafzadeh MJ, De Hoog GS, Meis JF, Randhawa HS, Chowdhary A. Molecular characterization and in vitro antifungal susceptibilities of 75 clinical Zygomycetes isolated in Delhi, India. Mycoses. 2012; 55: 108.
  • Khayhan K, Pan W, Hagen F, Simwami SP, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Meis JF, Klaassen CHW, Fisher M, Sriburee P, Boekhout T. Genotypic diversity and antifungal resistance of Cryptococcus neoformans from various asian countries. Mycoses. 2012; 55: 91.
  • Kloezen W, Meis JF, Curfs-Breuker I, Fahal AH, Van De Sande WWJ. In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother. 2012; 56(11): 6054-6056.
  • Lackner M, De Hoog GS, Geersten E, Verweij PE, Klaassen C, Meis JF. Species-specific, in-vitro, antifungal susceptibility patterns and epidemiological cut-off values for Scedosporium. Mycoses. 2012; 55: 43.
  • Lackner M, De Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, Meis JF. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012; 56(5): 2635-2642.
  • Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012; 8(6): 759-765.
  • Najafzadeh MJ, De Hoog GS, Saradeghi Keisari M, Klaassen CH, Meis J. In vitro activity of 8 antifungal drugs against 126 environmental and clinical isolates of Aureobasidium pullulans. Mycoses. 2012; 55: 116.
  • Pan W, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Imran D, Sjam R, Sriburee P, Liao W, Chaicumpar K, Ingviya N, Mouton JW, Curfs-Breuker I, Boekhout T, Meis JF, Klaassen CHW. Resistance of Asian Cryptococcus neoformans serotype a is confined to few microsatellite genotypes. PLoS ONE. 2012; 7(3).
  • Queiroz-Telles F. Implantation mycoses. Mycoses. 2012; 55: 74.
  • Queiroz-Telles F. New clinical and epidemiological scenarios for histoplasmosis. Mycoses. 2012; 55: 34.
  • Schmitt-Hoffmann A, F Richter W. Isavuconazole is widely distributed in rat tissue. Clin Microbiol Infect. 2012; 18: 183.
  • Smart J, Jones M, Azie N. In vitro activity of isavuconazole against 1488 Aspergillus isolates - A pooled analysis of nine studies. Clin Microbiol Infect. 2012; 18: 167. 
  • Verweij-van Wissen CPWGM, Burger DM, Verweij PE, Aarnoutse RE, Brüggemann RJM. Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J Chromatogr B Anal Technol Biomed Life Sci. 2012; (887-888): 79-84.
52nd Interscience Congress on Antimicrobial Agents and Chemotherapy ICAAC, September 2012, San Francisco, United States of America
  • A-1931 / Isavuconazole (ISA) Pharmacodynamic (PD) Target Determination for C. albicans (CA) in an In Vivo Neutropenic Murine Model of Invasive Candidiasis (IC). Lepak A, Marchillo K, Cabezas J, Andes DR.
  • M-331 / In Vitro Activity of Isavuconazole against Cryptococcus Isolates - A Pooled Analysis from 3 Studies. Smart JI, Jones ME, Kovanda LL.
  • A-1936 / Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of CYP3A4 Substrate Midazolam in Healthy Volunteers. Desai A, Zadeikis N, Pearlman H, Kowalski D, Townsend R.
  • M-332 / In Vitro Activity of Isavuconazole against a Worldwide Collection of 237 Aspergillus terreus Isolates and Compared with 7 Other Aspergillus Active Antifungal Drugs Tested with EUCAST and CLSI Methodology. Meis JF, Mouton JW, Bouchara JP, Chakrabarti A, Gaustad P, Guinea-Ortega JV, Houbraken J, Samson RA, Grif K, Lass-Floerl C, Klaassen CH.



52nd Interscience Congress on Antimicrobial Agents and Chemotherapy ICAAC, September 2012, San Francisco, United States of America
  • F-841 / In Vitro Activity of BAL30072 against Contemporary Clinical Isolates of Gram-Negative Bacteria (GNB) from New York City including Multidrug-Resistant (MDR) Isolates. Landman D, Singh M, El-Imad B, Miller E, Win T, Quale J.
  • E-193 / Antimicrobial Activity of BAL30072, Alone and in Combination with Meropenem Tested Against Gram-Negative Bacteria Causing Serious Infections in Hospitals from China, India, Latin America and South East Asia-Pacific. Rhomberg PR, Fedler KA, Flamm RK, Jones RN, Sader HS.
  • F-842 / Comparative Efficacy of BAL30072, Aztreonam, Meropenem and Ceftazidime and Effects of Dose Fractionation in a Murine Thigh Infection Model. Gould JK, Sattar A, Daws GM, Payne LJ, Spikermann J, Stubbings W, Schmitt-Hoffmann A, Page MGP, Warn PA.
  • A-1285 / Urinary Antibacterial Activity of BAL30072 against Uropathogens After IV Administration. Wagenlehner FME, Blenk B, Wagenlehner C, Blenk H, Naber KG.